Cargando…
Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50
BACKGROUND: Patients with stable atherothrombotic disease vary in their risk of developing heart failure (HF). Circulating cardiovascular biomarkers may improve HF risk assessment and identify patients who may benefit from emerging HF preventive therapies. METHODS AND RESULTS: We measured high‐sensi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200769/ https://www.ncbi.nlm.nih.gov/pubmed/33884889 http://dx.doi.org/10.1161/JAHA.120.018673 |
_version_ | 1783707678472667136 |
---|---|
author | Berg, David D. Freedman, Benjamin L. Bonaca, Marc P. Jarolim, Petr Scirica, Benjamin M. Goodrich, Erica L. Sabatine, Marc S. Morrow, David A. |
author_facet | Berg, David D. Freedman, Benjamin L. Bonaca, Marc P. Jarolim, Petr Scirica, Benjamin M. Goodrich, Erica L. Sabatine, Marc S. Morrow, David A. |
author_sort | Berg, David D. |
collection | PubMed |
description | BACKGROUND: Patients with stable atherothrombotic disease vary in their risk of developing heart failure (HF). Circulating cardiovascular biomarkers may improve HF risk assessment and identify patients who may benefit from emerging HF preventive therapies. METHODS AND RESULTS: We measured high‐sensitivity cardiac troponin I and BNP (B‐type natriuretic peptide) in 15 833 patients with prior myocardial infarction, ischemic stroke, or peripheral artery disease from the TRA 2°P‐TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events‐Thrombolysis in Myocardial Infarction 50) trial, excluding patients with recent myocardial infarction (<30 days). Biomarkers were categorized using a priori cut points. Hospitalization for HF (HHF) end points were adjudicated with blinded structured review of serious adverse events. Associations between biomarkers and HHF outcomes were adjusted for sex and independent clinical risk predictors of HHF in our cohort (age ≥75, prior HF, type 2 diabetes mellitus, polyvascular disease, body mass index, anemia, chronic kidney disease, hypertension). Baseline high‐sensitivity cardiac troponin I and BNP each identified a significant graded risk of HHF independent of clinical risk predictors, including in the subgroups of patients with and without type 2 diabetes mellitus and with and without prior HF. Patients with both high‐sensitivity cardiac troponin I ≥5 ng/L and BNP ≥100 pg/mL had the highest HHF event rates. When added to a multivariable Cox regression model with clinical risk predictors (C‐index 0.88; 95% CI, 0.85–0.90), BNP (C ‐index 0.92; 95% CI, 0.90–0.93), and high‐sensitivity cardiac troponin I (C‐index 0.90; 95% CI, 0.88–0.92) each significantly improved the prognostic performance of the model (both P (LRT)<0.001). CONCLUSIONS: Biomarkers of myocardial injury and hemodynamic stress are independent predictors of HHF risk in patients with stable atherothrombotic disease, with and without prior HF and/or type 2 diabetes mellitus. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00526474. |
format | Online Article Text |
id | pubmed-8200769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82007692021-06-15 Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50 Berg, David D. Freedman, Benjamin L. Bonaca, Marc P. Jarolim, Petr Scirica, Benjamin M. Goodrich, Erica L. Sabatine, Marc S. Morrow, David A. J Am Heart Assoc Original Research BACKGROUND: Patients with stable atherothrombotic disease vary in their risk of developing heart failure (HF). Circulating cardiovascular biomarkers may improve HF risk assessment and identify patients who may benefit from emerging HF preventive therapies. METHODS AND RESULTS: We measured high‐sensitivity cardiac troponin I and BNP (B‐type natriuretic peptide) in 15 833 patients with prior myocardial infarction, ischemic stroke, or peripheral artery disease from the TRA 2°P‐TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events‐Thrombolysis in Myocardial Infarction 50) trial, excluding patients with recent myocardial infarction (<30 days). Biomarkers were categorized using a priori cut points. Hospitalization for HF (HHF) end points were adjudicated with blinded structured review of serious adverse events. Associations between biomarkers and HHF outcomes were adjusted for sex and independent clinical risk predictors of HHF in our cohort (age ≥75, prior HF, type 2 diabetes mellitus, polyvascular disease, body mass index, anemia, chronic kidney disease, hypertension). Baseline high‐sensitivity cardiac troponin I and BNP each identified a significant graded risk of HHF independent of clinical risk predictors, including in the subgroups of patients with and without type 2 diabetes mellitus and with and without prior HF. Patients with both high‐sensitivity cardiac troponin I ≥5 ng/L and BNP ≥100 pg/mL had the highest HHF event rates. When added to a multivariable Cox regression model with clinical risk predictors (C‐index 0.88; 95% CI, 0.85–0.90), BNP (C ‐index 0.92; 95% CI, 0.90–0.93), and high‐sensitivity cardiac troponin I (C‐index 0.90; 95% CI, 0.88–0.92) each significantly improved the prognostic performance of the model (both P (LRT)<0.001). CONCLUSIONS: Biomarkers of myocardial injury and hemodynamic stress are independent predictors of HHF risk in patients with stable atherothrombotic disease, with and without prior HF and/or type 2 diabetes mellitus. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00526474. John Wiley and Sons Inc. 2021-04-22 /pmc/articles/PMC8200769/ /pubmed/33884889 http://dx.doi.org/10.1161/JAHA.120.018673 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Berg, David D. Freedman, Benjamin L. Bonaca, Marc P. Jarolim, Petr Scirica, Benjamin M. Goodrich, Erica L. Sabatine, Marc S. Morrow, David A. Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50 |
title | Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50 |
title_full | Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50 |
title_fullStr | Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50 |
title_full_unstemmed | Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50 |
title_short | Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50 |
title_sort | cardiovascular biomarkers and heart failure risk in stable patients with atherothrombotic disease: a nested biomarker study from tra 2°p‐timi 50 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200769/ https://www.ncbi.nlm.nih.gov/pubmed/33884889 http://dx.doi.org/10.1161/JAHA.120.018673 |
work_keys_str_mv | AT bergdavidd cardiovascularbiomarkersandheartfailureriskinstablepatientswithatherothromboticdiseaseanestedbiomarkerstudyfromtra2ptimi50 AT freedmanbenjaminl cardiovascularbiomarkersandheartfailureriskinstablepatientswithatherothromboticdiseaseanestedbiomarkerstudyfromtra2ptimi50 AT bonacamarcp cardiovascularbiomarkersandheartfailureriskinstablepatientswithatherothromboticdiseaseanestedbiomarkerstudyfromtra2ptimi50 AT jarolimpetr cardiovascularbiomarkersandheartfailureriskinstablepatientswithatherothromboticdiseaseanestedbiomarkerstudyfromtra2ptimi50 AT sciricabenjaminm cardiovascularbiomarkersandheartfailureriskinstablepatientswithatherothromboticdiseaseanestedbiomarkerstudyfromtra2ptimi50 AT goodricherical cardiovascularbiomarkersandheartfailureriskinstablepatientswithatherothromboticdiseaseanestedbiomarkerstudyfromtra2ptimi50 AT sabatinemarcs cardiovascularbiomarkersandheartfailureriskinstablepatientswithatherothromboticdiseaseanestedbiomarkerstudyfromtra2ptimi50 AT morrowdavida cardiovascularbiomarkersandheartfailureriskinstablepatientswithatherothromboticdiseaseanestedbiomarkerstudyfromtra2ptimi50 |